Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
136.19B
Market cap136.19B
Price-Earnings ratio
18.46
Price-Earnings ratio18.46
Dividend yield
7.14%
Dividend yield7.14%
Average volume
60.91M
Average volume60.91M
High today
$24.24
High today$24.24
Low today
$23.74
Low today$23.74
Open price
$24.15
Open price$24.15
Volume
49.36M
Volume49.36M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.11
52 Week low$23.11

Stock Snapshot

With a market cap of 136.19B, Pfizer(PFE) trades at $23.90. The stock has a price-to-earnings ratio of 18.46 and currently yields dividends of 7.14%.

During the trading session on 2026-07-01, Pfizer(PFE) shares reached a daily high of $24.24 and a low of $23.74. At a current price of $23.90, the stock is +0.7% higher than the low and still -1.4% under the high.

Trading volume for Pfizer(PFE) stock has reached 49.36M, versus its average volume of 60.91M.

The stock's 52-week range extends from a low of $23.11 to a high of $28.75.

The stock's 52-week range extends from a low of $23.11 to a high of $28.75.

PFE News

TipRanks 7h
Pfizer Expands Migraine Strategy With New Rimegepant Redosing Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

TipRanks 7h
Cboe data shows mixed options sentiment in Pfizer with shares down 0.77%

Cboe data shows mixed options sentiment in Pfizer (PFE), with shares down 18c near $23.89. Options volume relatively light with 29k contracts traded and calls l...

TipRanks 1d
Pfizer’s Real‑World COVID-19 Vaccine Study Nears Data Reveal: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

Analyst ratings

59%

of 29 ratings
Buy
34.5%
Hold
58.6%
Sell
6.9%

More PFE News

24/7 Wall St. 1d
Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat

Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat By Alex Sirois Published Jun 30, 12:15PM EDT Quick Read PFE offers a nearly 7...

Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat
Nasdaq 1d
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock

Key Points Pfizer's acquisition of Metsera last year opens up some exciting opportunities in the GLP-1 space. It wants to be a leader in obesity therapies. W...

Why Pfizer Could Prove to Be an Underrated GLP-1 Stock
Simply Wall St 2d
Will FDA’s New IBRANCE (palbociclib) Maintenance Approval Reshape Pfizer’s Oncology Narrative?

Earlier this month, Pfizer received U.S. FDA approval for expanding IBRANCE (palbociclib) to maintenance treatment of adults with HR+, HER2+ locally advanced or...

Will FDA’s New IBRANCE (palbociclib) Maintenance Approval Reshape Pfizer’s Oncology Narrative?
Simply Wall St 3d
Pfizer Could Be 13% Undervalued On Mixed Oncology News And CFO Change

Pfizer (PFE) is in focus after investors were hit with mixed oncology news, a planned CFO transition, and fresh questions around its pipeline, all set against t...

Pfizer Could Be 13% Undervalued On Mixed Oncology News And CFO Change
Nasdaq 4d
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?

Key Points One of Pfizer's promising oncology candidates recently failed a phase 3 study. The drugmaker is also losing its CFO. Despite the challenges, there...

A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?
Nasdaq 4d
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

Key Points Pfizer is one of the world's largest drug companies. It has a long history of navigating the industry's ups and downs. Pfizer is struggling today,...

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
The Motley Fool 4d
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends

Looking for stocks that pay dividends? You may have come across pharmaceutical outfit Pfizer (PFE +2.62%) in your search. After all, its forward-looking dividen...

Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.